Cutera Inc
CUTR
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
10950.8% upsideUndervalued by 10950.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.96 Million |
|---|---|
| Enterprise Value | $384.93 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.19 |
| Beta | 1.37 |
| Outstanding Shares | 20,154,000 |
Return
| Return on Equity | 52.08% |
|---|---|
| Return on Assets | -56.18% |
| Return on Invested Capital | -73.56% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.1 |
| Price to Sales | 0.01 |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | 2.48 |
| Enterprise Value to EBIT | -2.93 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 1.14 |
| Debt to Equity | -1.74 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cutera Inc
CEO: David Mowry Relevant Senate Committees
This committee provides the official revenue estimates and technical analysis for all tax legislation, directly influencing corporate tax structures and capital investment credits relevant to Cutera's financial performance.
This powerful committee controls taxation (impacting profitability), trade (affecting costs/sales), and entitlement spending like Medicare pricing, which directly influences reimbursement for medical devices and demand.
This committee has direct oversight of the FDA, which is the primary regulatory body for medical devices, significantly impacting Cutera's product approvals and market access.
The committee's oversight of intellectual property (patents for medical devices) and antitrust laws (impacting mergers/acquisitions in the medical device sector) directly affects Cutera's legal environment and competitive strategy.